Arovella Therapeutics Ltd has released a press release.
Preliminary Final Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Quarterly Appendix 4C and Activities Report
- Sumatriptan Update
- ZolpiMist Launch Australia
- Adopts WEF Framework For ESG Reporting
- Services Agreement with Q-Gen for CAR19-iNKT manufacture
Later from Arovella Therapeutics
- Preclinical trial of ALA iNKT therapy and IMU onCARlytics
- Arovella to close its Perth OroMist R&D Facility
- Europe Patent granted for iNKT Cell Therapy Platform
- R&D Tax Incentive refund received
- Arovella completes $1.65M placement
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics